Dyadic International, Inc. (NASDAQ:DYAI) (the "Company"), d/b/a Dyadic Applied BioSolutions,

JUPITER, Fla., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI) (the “Com

Dyadic International, Inc. (DYAI) Q2 2026 Earnings Call Transcript

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the a

JUPITER, Fla., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “

Dyadic International (NASDAQ: DYAI - Get Free Report) and Myriad Genetics (NASDAQ: MYGN - Get Free R

Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic

JUPITER, Fla., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic"

JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied Bio

JUPITER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic”

Dyadic International, Inc. (NASDAQ:DYAI) ("Dyadic" or the "Company"), d/b/a Dyadic A

JUPITER, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic”

Gainers China Pharma Holding (AMEX:CPHI) shares increased by 713.2% to $7.4 during Tuesday's re

JUPITER, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) ("Dyadic"

Global Collaborations Continue to Validate Dyadic's C1 Platform and Expand Commercial Opportunity Dy

The Japan Patent Office allowed claims covering novel aspects of Dyadic’s proprietary Thermothelomyc

JUPITER, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI) (“Dyadic”

SmallCaps Daily Sits Down with Joe Hazelton to Discuss Dyadic's Product Strategy, Strategic Partners

Dyadic International, Inc. (NASDAQ:DYAI), d/b/a Dyadic Applied BioSolutions ("Dyadic" or the

JUPITER, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (Nasdaq: DYAI), d/b/a Dy

https://www.state.gov/releases/office-of-the-spokesperson/2026/06/ebola-response-update-june-5-2026/

A series of recently reported hantavirus and Ebola cases worldwide have underscored the importance o

JUPITER, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic,” “we,” “us,” “o

JUPITER, Fla., May 21, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “o

Company invites individual and institutional investors, as well as advisors and analysts, to attend

JUPITER, Fla. , May 19, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic," "we," "us," "

Dyadic International, Inc. (DYAI) Q1 2026 Earnings Call Transcript

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.05) per share which missed the a

Received initial purchase orders for recombinant bovine transferrin from customers in the cultivated

On March 27, 2026, Dyadic International, Inc. (the "Company" or "Dyadic") received a

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the a

Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the &#3

Completion of these development activities represents a contractual milestone under the parties'

Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the &#3

Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the &#3

Under the agreement, Opes will leverage its existing commercial relationships and market experience

QTTB: 97% | Q32 Bio Sells Phase 2 Complement Inhibitor ADX-097 To Akebia Therapeutics For $12M Upfro

Dyadic Applied BioSolutions ("Dyadic"), a global biotechnology company producing precision-e

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which missed the a

ERS Genomics Limited (‘ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a g

HC Wainwright & Co. analyst Swayampakula Ramakanth assumes Dyadic International (NASDAQ:DYAI)

Dyadic International (NASDAQ:DYAI) reported quarterly losses of $(0.06) per share which met the anal